Abcam, ab250778, Anti-PKC alpha + beta 2 + gamma antibody [EPR18104] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal KPCB antibody. Carrier free. Suitable for ICC/IF, WB, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18104,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:ICC/IF, IHC-P, WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250778 is the carrier-free version of
ab184746
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Protein kinase C (PKC) isozymes alpha beta 2 and gamma are serine/threonine kinases that play a pivotal role in signal transduction processes. PKC isozymes have alternate common names such as PRKCA for PKC alpha PRKCB for PKC beta 2 and PRKCG for PKC gamma. These proteins have variable molecular masses with PKC alpha around 79 kDa PKC beta 2 approximately 80 kDa and PKC gamma also about 81 kDa. PKC alpha is expressed ubiquitously PKC beta 2 shows high expression in hematopoietic cells and PKC gamma is primarily found in the brain and spinal cord.
Biological function summary
PKC alpha beta 2 and gamma participate in cellular processes like proliferation differentiation and apoptosis. These isozymes do not typically form a part of large protein complexes but operate through direct interactions with other proteins and lipids to convey signals. They modulate cytoskeletal proteins and transcription factors altering the cell's behavior in response to extracellular cues. Their activation occurs via phospholipid-mediated signals and is calcium and diacylglycerol dependent.
Pathways
PKC alpha beta 2 and gamma are integral to the phosphoinositide signaling pathway and the MAPK/ERK pathway. By phosphorylating various proteins these isozymes influence the downstream activation of key factors within these pathways. For instance PKC alpha interrupts glycogen synthase kinase 3 beta (GSK-3β) while PKC gamma connects to synaptic plasticity processes. Their specific actions coordinate signaling cascades that orchestrate diverse cellular responses.
PKC isozymes are associated with cancer and neurological disorders. PKC alpha and beta 2 display aberrant activity in several cancer types often influencing tumor growth and survival. Meanwhile PKC gamma mutations commonly relate to the development of neuropathic conditions like spinocerebellar ataxia. Furthermore PKC alpha's interaction with tumor suppressor p53 implies a role in oncogenesis. Understanding these relationships helps in targeting PKC isozymes for therapeutic interventions.